Abstract
Crohn’s disease and ulcerative colitis belong to a group of inflammatory bowel diseases (IBD). IBD are characterized by a chronic character of inflammatory process and overlapping immunological abnormalities, which, along with therapeutic strategies are currently available, underlie an increased risk of venous thromboembolic events (VTE). The most common sites of VTE in IBD patients are deep venous thrombosis (DVT) and pulmonary embolism (PE). These complications are particularly important in clinical practice due to a very high mortality rate. Therefore, an early diagnosis of new IBD cases and the control of inflammatory process are thought to play a crucial role in risk reduction for thromboembolic events. Despite considerable evidence supporting the association between IBD and VTE, there is still a lack of recognition of this risk, with dangerous consequences for patients. In this paper authors report three cases of VTE in IBD patients and discuss the most relevant clinical studies found in MEDLINE, Cochrane Library and EMBASE regarding its prevention and management.
Keywords: Anticoagulants, inflammatory bowel diseases, low molecular weight heparin, thromboembolic prophylaxis, venous thromboembolism.
Current Drug Targets
Title:Prevention and Therapeutic Strategies of Thromboembolic Events in Patients with Inflammatory Bowel Diseases: A Report of Three Cases
Volume: 16 Issue: 3
Author(s): Marcin Wlodarczyk, Aleksandra Sobolewska, Jakub Fichna and Maria Wisniewska-Jarosinska
Affiliation:
Keywords: Anticoagulants, inflammatory bowel diseases, low molecular weight heparin, thromboembolic prophylaxis, venous thromboembolism.
Abstract: Crohn’s disease and ulcerative colitis belong to a group of inflammatory bowel diseases (IBD). IBD are characterized by a chronic character of inflammatory process and overlapping immunological abnormalities, which, along with therapeutic strategies are currently available, underlie an increased risk of venous thromboembolic events (VTE). The most common sites of VTE in IBD patients are deep venous thrombosis (DVT) and pulmonary embolism (PE). These complications are particularly important in clinical practice due to a very high mortality rate. Therefore, an early diagnosis of new IBD cases and the control of inflammatory process are thought to play a crucial role in risk reduction for thromboembolic events. Despite considerable evidence supporting the association between IBD and VTE, there is still a lack of recognition of this risk, with dangerous consequences for patients. In this paper authors report three cases of VTE in IBD patients and discuss the most relevant clinical studies found in MEDLINE, Cochrane Library and EMBASE regarding its prevention and management.
Export Options
About this article
Cite this article as:
Wlodarczyk Marcin, Sobolewska Aleksandra, Fichna Jakub and Wisniewska-Jarosinska Maria, Prevention and Therapeutic Strategies of Thromboembolic Events in Patients with Inflammatory Bowel Diseases: A Report of Three Cases, Current Drug Targets 2015; 16 (3) . https://dx.doi.org/10.2174/1389450115666141109213152
DOI https://dx.doi.org/10.2174/1389450115666141109213152 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Treating Nonthyroidal Illness Syndrome in the Critically Ill Patient: Still a Matter of Controversy
Current Drug Targets Therapeutic Use of Antioxidants in Sepsis
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Development of Anti-Atherosclerosis Therapy Based on the Inflammatory and Proliferative Aspects of the Disease
Current Pharmaceutical Design Vitamin D Intervention Trials in Critical Illness
Inflammation & Allergy - Drug Targets (Discontinued) Pulmonary Manifestations of Rheumatoid Arthritis, Psoriatic Arthritis and Peripheral Spondyloarthritis: Prevalence, Diagnostic Approach and Treatment Options
Current Rheumatology Reviews Therapeutic Implications of Tocilizumab, A Humanized Anti-Interleukin-6 Receptor Antibody, for Various Immune-Mediated Diseases: An Update Review
Current Rheumatology Reviews Renal Phosphate Handling in Antiretroviral-naive HIV-Infected Patients
Infectious Disorders - Drug Targets Initiation of the Immune Response by Extracellular Hsp72: Chaperokine Activity of Hsp72
Current Immunology Reviews (Discontinued) Recent Patents on Live Bacteria and their Products as Potential Anticancer Agents
Recent Patents on Anti-Cancer Drug Discovery Women’s Health in Central America: The Complexity of Issues and the Need to Focus on Indigenous Healthcare
Current Women`s Health Reviews Adipokines, Metabolism and the Immune Response in the Regulation of Inflammation
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Role of Moving Average Analysis for Development of Multi-Target (Q)SAR Models
Mini-Reviews in Medicinal Chemistry Pharmacological Drug Delivery Strategies for Improved Therapeutic Effects: Recent Advances
Current Pharmaceutical Design Fragment Pharmacophore-Based Screening: An Efficient Approach for Discovery of New Inhibitors of Toll-Like Receptor 5
Combinatorial Chemistry & High Throughput Screening Recent Patents on Proteases and Kinases as Anti-Infective Agents: A Review
Recent Patents on Anti-Infective Drug Discovery Nano-Therapeutics for the Lung: State-of-the-Art and Future Perspectives
Current Pharmaceutical Design Pharmaceutical Care: Past, Present and Future
Current Pharmaceutical Design Managing the Liabilities Arising from Structural Alerts: A Safe Philosophy for Medicinal Chemists
Current Medicinal Chemistry The Coronin Family and Human Disease
Current Protein & Peptide Science Emergence of Lipid-Based Vesicular Carriers as Nanoscale Pharmacotherapy in Rheumatoid Arthritis
Recent Patents on Nanomedicine